VIP/VeIP first-salvage study
What activity was observed with ifosfamide/cisplatin-based VIP or VeIP as first salvage treatment?
Mixed GCT cohort
Study population as reported in the cited publication; cohort sizes and denominators are stated where available.
Not all evidence is randomized, comparative, or seminoma-specific.
Reported outcomes
Among 56 assessable patients treated with ifosfamide/cisplatin plus either vinblastine (VeIP) or etoposide (VIP), 20 (36%) achieved complete response and 13 (23%) were continuously disease-free at median follow-up of 52 months.
Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.
Interpretation and limitations
Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.
Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025
Primary study source
McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15:2559–2563.
Original study / PubMed / registry ↗
Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.